Navigation Links
XTENT Announces 2007 Financial Results Conference Call
Date:2/12/2008

MENLO PARK, Calif., Feb. 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) announced that it will report its financial results for 2007 after market close on Tuesday, February 19, 2008. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gregory D. Casciaro, XTENT's President and Chief Executive Officer, and Tim Kahlenberg, Chief Financial Officer.

The teleconference can be accessed via the investor relations section of the company's website at http://investor.xtentinc.com/events.cfm or by calling 877-627-6580 (domestic), 719-325-4903 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call.

An online archive of the webcast will be available for a minimum of three months by accessing the investor relations portion of the company's website at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
2. XTENT Announces Third Quarter 2007 Financial Results
3. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
4. USHEALTH Group Announces Appointment of Executive Vice President
5. Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
6. Herley Industries Announces the Passing of Its Former President
7. GPhA Announces 2008-2009 Executive Committee; Teva North Americas Bill Marth Elected as Chairman of the Board
8. Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil
9. Methodist Healthcare - Memphis Hospitals Announces the Commencement of the Tender Offer for Certain Designated Maturities of:
10. Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis Pathogen Identification Technology
11. Sosei Announces Start of AD 923 Phase III Studies in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that ... for Texas, they are expanding their presence in Dallas. One of the most exciting ... bring new jobs to the Dallas and Forth Worth market. STAT takes pride in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... Texas , Dec. 8, 2016 ... program that brings leading-edge laboratory services and management ... United States , allowing more doctors and ... health care management solutions. Logo - ... Hospital systems, under pressure to contain ...
(Date:12/8/2016)... Information products and services provider Elsevier has ... the world,s largest abstract and citation database of peer-reviewed literature, providing ... over 5,000 publishers. The new set of metrics will improve decisions ... to adjust a journal,s editorial strategy. ... , , CiteScore metrics ...
Breaking Medicine Technology: